Hidradenitis suppurativa
Conditions
Interventions
Moderate to severe HS patient group:None
Sponsors
Hospital for Skin Disease, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with purulent sweat gland inflammation (HS) aged 18 (inclusive) to 80 (inclusive), with a clinical severity level of Moderate to severe (Hurley II-III grade), regardless of gender. 2. Confirmed as HS through histopathological examination by the pathology department of our hospital. 3. HS patients receiving combined surgical treatment with Sikuximab in the dermatology department of our hospital. 4. Patients with complete clinical data and a follow-up period of at least 1 year.
Exclusion criteria
Exclusion criteria: 1. Missing patients. 2. Patients who have been followed up for less than one year. 3. Patients who receive additional adjuvant therapy during the follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HiSCR scores;IHS4 scores;The decreased number of inflammatory nodules ;The decreased number of abscess;The decreased number of sinus tracts;Reduce the degree of skin pain;The safety of the drug, paying attention to the presence of any related adverse reactions or complications;Improvement of the patient's quality of life score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The onset time of the drug;The duration of the drug's therapeutic effect;Reduction of inflammatory markers (such as white blood cells, erythrocyte sedimentation rate, C-reactive protein, etc.);The convenience of drug use;Reduction of the impact on the patient's work productivity; | — |
Countries
China
Contacts
Public ContactBu Wenbo
Hospital for Skin Disease, Chinese Academy of Medical Sciences
Outcome results
None listed